Entia Biosciences Inc ERGO

$0.00 +0.00 (400.00%)

Valuation

Market cap
0
Revenue TTM
$270,000
Net income TTM
$-1,400,000
PE ratio
0.00
Forward PE
—
Profit margin
-518.52%
Debt to equity
0.00

Trading

Volume
500
Avg volume
—
Day's range
$0.00 – $0.00
Shares out
—
Stochastic %K
100%
Beta
27.08
Analysts
Strong Buy
Price target
—

Price

Company profile

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also invol...

Show more

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.

Industry
Biotechnology
Sector
Healthcare
Phone
971-228-0709
Address
13565 SW Tualatin-Sherwood Road, Suite 800, Sherwood, United States

Latest news

No headlines yet.